ストックスクリーナーアプリを入手
3.17
1.12%
0.04
前日終値:
$3.13
開ける：
$3.12
24時間の取引高:
647.99K
Relative Volume:
0.33
時価総額：
$215.22M
収益：
-
当期純損益:
$-292.19M
株価収益率:
-0.6604
EPS:
-4.8
ネットキャッシュフロー:
$-208.41M
1週間 パフォーマンス:
-19.87%
1か月 パフォーマンス:
-1.09%
6か月 パフォーマンス:
-72.67%
1年 パフォーマンス:
-69.42%
1日の値動き範囲:
$2.99
$3.21
1週間の範囲:
$2.90
$4.00
52週間の値動き範囲:
$2.66
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ZNTL | 3.175 | 215.22M | 0 | -292.19M | -208.41M | -4.80 |
| VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.93 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
What is HC Wainwright's Estimate for ZNTL Q3 Earnings? - MarketBeat
Leerink Partnrs Has Bullish Outlook for ZNTL FY2024 Earnings - MarketBeat
Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright - MarketBeat
Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat
Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com
ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks
Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Zentalis Pharma Reshapes Leadership, Advances Cancer Drug Azenosertib Toward Key Trials | ZNTL Stock News - StockTitan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL): Worth A Small Bite At $3.81 - Stocks Register
Eventide Asset Management's Strategic Reduction in Zentalis Phar - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada
Undervalued Opportunities: US Penny Stocks To Watch In October 2024 - Simply Wall St
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Stock sold by Insider Vultaggio Vincent for $5098.0 - Knox Daily
Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News - Yahoo Finance
Balance Sheet Insights: Zentalis Pharmaceuticals Inc (ZNTL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 26.2% - MarketBeat
ZNTL Shares Experience Decline in Value - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from Brokerages - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Insider Vultaggio Vincent sells 1,603 Shares – Company Insider Activity - Knox Daily
Results from Zentalis Pharmaceuticals Inc (ZNTL) show risk - US Post News
Zentalis Pharmaceuticals Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc - Yahoo Finance
Stock Market Recap: Zentalis Pharmaceuticals Inc (ZNTL) Concludes at 3.37, a 5.31 Surge/Decline - The Dwinnex
Zentalis Pharmaceuticals executive sells over $5,000 in company stock By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals executive sells over $5,000 in company stock - Investing.com India
ZNTL’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully - Simply Wall St
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why - MSN
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
A Look at Zentalis Pharmaceuticals Inc (ZNTL) Shares in the Recent Past Indicates Growth - SETE News
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Holdings Raised by Renaissance Technologies LLC - MarketBeat
Results from Zentalis Pharmaceuticals Inc (ZNTL) show potential - US Post News
Zentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News Summary - Benzinga
Decheng Capital LLC Has $12.56 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Holdings of Zentalis Pharmaceuticals Inc (ZNTL) are aligned with the stars - SETE News
Analyzing Ratios: Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Story Unveiled - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
Zentalis Pharmaceuticals Inc (ZNTL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | Principal Accounting Officer |
Oct 04 '24 |
Sale |
3.18 |
1,603 |
5,098 |
33,855 |
| Gallagher Cam | President, Interim CFO |
May 31 '24 |
Sale |
11.98 |
9,597 |
114,972 |
633,680 |
| HAUSMAN DIANA | Chief Medical Officer |
May 09 '24 |
Sale |
12.62 |
3,356 |
42,353 |
373,876 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 12 '24 |
Sale |
11.44 |
2,573 |
29,435 |
451,449 |
| Gallagher Cam | President |
Feb 12 '24 |
Sale |
11.44 |
1,173 |
13,419 |
643,277 |
| Lackner Mark | Chief Scientific Officer |
Feb 02 '24 |
Sale |
11.54 |
1,585 |
18,291 |
195,728 |
| Paul Andrea | Chief Legal Officer |
Feb 02 '24 |
Sale |
11.54 |
3,310 |
38,197 |
149,973 |
| Gallagher Cam | President |
Feb 02 '24 |
Sale |
11.54 |
11,552 |
133,310 |
644,450 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 02 '24 |
Sale |
11.54 |
8,669 |
100,040 |
454,022 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):